Rezultaty - Ada Azaryan
- Rezultaty 1 - 3 Rezultaty od 3
-
1
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study od Peter Schäfer, Alan Kivitz, Jianglin Ma, Shimon Korish, Donna Sutherland, Li Li, Ada Azaryan, Jolanta Kosek, Mary Adams, Lori Capone, Eun Mi Hur, Douglas R. Hough, Garth E. Ringheim
Wydane 2019Artigo -
2
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study od Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim Linton, Martine E.D. Chamuleau, David John Lewis, Anna Sureda, David Cunningham, Roberto S Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Kuo-mei Chen, Tahamtan Ahmadi, Pieternella J. Lugtenburg
Wydane 2021Artigo -
3
Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia od Jennifer R. Brown, Wael A. Harb, B. T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, TP Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Y. Li, Daniel W. Pierce, Elizabeth D. Barnett, Joseph E. Marine, Michele Miranda, Ada Azaryan, Xu Y, Pilar Nava-Parada, Jay Mei, Thomas J. Kipps
Wydane 2016Carta
Narzędzie wyszukiwania:
Podobne hasła
Internal medicine
Medicine
Biology
Lymphoma
Oncology
Receptor
Tyrosine kinase
Adverse effect
Antibody
Astrobiology
Bruton's tyrosine kinase
CD23
CD34
CD38
CXCL13
Cancer research
Chemistry
Chemokine
Chemokine receptor
Chronic lymphocytic leukemia
Clinical trial
Cytokine
Gastroenterology
Genetics
Ibrutinib
Immune system
Immunoglobulin E
Immunology
Inflammation
Leukemia